Azitra, Inc. (AZTR)
$
0.28
Key metrics
Financial statements
Free cash flow per share
-233.7789
Market cap
4.5 Million
Price to sales ratio
0.6019
Debt to equity
0.1075
Current ratio
3.0237
Income quality
1.0015
Average inventory
0
ROE
-2.7803
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on precision dermatology through the development of engineered proteins and live biotherapeutic products aimed at treating various skin diseases. The income before tax ratio is -1,194.46 reflecting the pre-tax margin that the company has achieved through its research and development efforts. The net income ratio is -1.20 reflecting the company's profitability margin as it navigates the complex landscape of biopharmaceutical innovation. The weighted average number of shares outstanding is 3,780,000.00 highlighting the company's shareholder base, which plays a crucial role in its financial stability and growth. The weighted average number of diluted shares outstanding is 3,780,000.00 reflecting potential dilution effects that could arise from future financing activities. Additionally, the company incurred an interest expense of $12,160.00 reflecting its debt servicing obligations which are an important consideration for investors. Azitra is currently developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, ATR-04 for addressing the papulopustular rash in cancer patients undergoing epidermal growth factor receptor inhibitors, and ATR-01, an engineered recombinant human filaggrin protein for ichthyosis vulgaris. The stock is affordable at $0.27 making it suitable for budget-conscious investors who are looking to tap into promising biopharmaceutical ventures. Despite its potential, the stock has a low average trading volume of 1,434,876.00 indicating lower market activity which may impact liquidity. Nevertheless, with a market capitalization of $4,738,970.00 the company is classified as a small-cap player, and this status often provides unique opportunities for growth. Azitra is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative therapeutic approaches. It belongs to the Healthcare sector, driving innovation and growth that can lead to advancements in treatment options for patients suffering from challenging dermatological conditions.
Is Azitra, Inc. (AZTR) a good investment?
Investing in Azitra, Inc. (AZTR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Azitra, Inc. (AZTR)'s stock forecast?
Analysts predict Azitra, Inc. stock to fluctuate between $0.23 (low) and $12 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Azitra, Inc.'s market capitalization?
As of 2025-06-06, Azitra, Inc.'s market cap is $4,738,970, based on 17,226,355 outstanding shares.
How does Azitra, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Azitra, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Azitra, Inc. (AZTR) stock?
To buy Azitra, Inc. (AZTR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AZTR. Place an order (Market, Limit, etc.).
What is the best time to invest in Azitra, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Azitra, Inc. stock ever split?
Azitra, Inc.'s last stock split was 1:30 on 2024-07-01.
How did Azitra, Inc. perform in the last earnings report?
Revenue: $7,500,000 | EPS: -$2.37 | Growth: -95.15%.
Where can I find Azitra, Inc.'s investor relations reports?
Visit https://azitrainc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Azitra, Inc.?
You can explore historical data from here
What is the all-time high and low for Azitra, Inc. stock?
All-time high: $155.40 (2023-06-16) | All-time low: $0.23 (2025-01-24).
What are the key trends affecting Azitra, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
10 days ago
BRANFORD, Conn. , May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago.
prnewswire.com
24 days ago
Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash BRANFORD, Conn. , May 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor ("EGFRi")-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
prnewswire.com
25 days ago
BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update.
prnewswire.com
a month ago
Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2025 in Chicago.
prnewswire.com
a month ago
BRANFORD, Conn. , April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor.
prnewswire.com
3 months ago
BRANFORD, Conn. , March 12, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Chief Operating Officer, Travis Whitfill, Ph.D.
prnewswire.com
3 months ago
BRANFORD, Conn. , Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update.
prnewswire.com
4 months ago
BRANFORD, Conn. , Feb. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with certain institutional investor(s) to purchase 3,339,300 shares of common stock at an offering price of $0.2785 per share, in a registered direct offering.
prnewswire.com
4 months ago
BRANFORD, Conn. , Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at the BIO CEO & Investor Conference being held February 10-11, 2025, in New York City.
prnewswire.com
4 months ago
BRANFORD, Conn. , Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, NJ.
See all news
